Single nucleotide polymorphisms and unacceptable late toxicity in breast cancer adjuvant radiotherapy: a case report

Grazia Lazzari1
Maria Iole Natalicchio2
Angela Terlizzi3
Francesco Perri4
Giovanni Silvano1

1Radiation Oncology Unit, San Giuseppe Moscati Hospital, Taranto, 2Molecular Biology Laboratory, Pathological Anatomy Department, Ospedali Riuniti, Fogia, 3Medical Physic Unit, San Giuseppe Moscati Hospital, 4Medical Oncology Unit, Presidio Ospedaliero Centrale - Santissima Annunziata, Taranto, Italy

Background: There has recently been a strong interest in the inter-individual variation in normal tissue and tumor response to radiotherapy (RT), because tissue radiosensitivity seems to be under genetic control. Evidence is accumulating on the role of polymorphic genetic variants, such as single nucleotide polymorphisms (SNPs) that could influence normal tissue response after radiation. The most studied SNPs include those in genes involved in DNA repair (single- and double-strand breaks, and base excision) and those active in the response to oxidative stress.

Case report: We present the case report of a 60-year-old woman with early breast cancer who underwent adjuvant hormone therapy and conventional radiotherapy, and subsequently developed unacceptable cosmetic toxicities of the irradiated breast requiring a genetic test of genes involved in DNA repair mechanisms. The patient was found to be heterozygous for G28152A (T/C) and C18067T (A/G) mutations in X-ray repair cross-complementing group 1 (XRCC1) and 3 (XRCC3), respectively, homozygous for A313G (G/G) mutation in glutathione S transferase Pi 1 (GSTP1), and wild-type for A4541G (A/A) in XRCC and G135C (G/G) in RAD51 recombinase.

Conclusion: The role of SNPs should be taken into account when a severe phenomenon appears in normal tissues after radiation treatment, because understanding the molecular basis of individual radiosensitivity may be useful for identifying moderately or extremely radiosensitive patients who may need tailored therapeutic strategies.

Keywords: radiosensitivity, SNPs, fibrosis, DNA repair

Introduction

Adjuvant radiotherapy (RT) in breast cancer after conservative surgery has become a widely accepted standard of care for patients with early breast cancer. Early Breast Cancer Trialists’ Collaborative Group meta-analysis has clearly demonstrated that adjuvant RT after breast-conserving surgery (BCS) reduces the 10-year risk of any locoregional or distant first recurrence from 35% to 19.3% (2p<0.00001) and the 15-year risk of breast cancer deaths from 25.2% to 21.4% (2p<0.00001). However, RT acts on tumors and the surrounding normal tissues but could cause acute and late side effects, which could range from mild to severe depending on fractionation size and α/β ratio of involved tissues. Acute normal tissue toxicity that appears as edema, swelling, and epithelial stripping is generally a transient phenomenon, while late normal tissue toxicities, such as telangiectasias, tissue fibrosis with functional tissue impairment, and skin retraction with poor cosmesis, are progressive and permanent findings. These acute and late normal tissue radiation-induced toxicities are strongly related to individual radiosensitivity that could vary widely from patient to patient.
Tissue hypoxia, drugs employed, and genetic features may also affect the clinical tissue radiosensitivity after a normal fractionated schedule. Drugs such as chemotherapy or hormone therapy have been demonstrated to enhance subcutaneous fibrosis after radiotherapy as reported by Skoczylas et al and Bentzen et al who analyzed the impact of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or tamoxifen on cosmesis.3,4 On the other hand, the use of aromatase inhibitors seems to exert a protective effect on post-radiation-induced lung fibrosis.5 Once pharmacologic causes have been excluded, radiation-induced late tissue injury could be due to altered DNA sequences such as single nucleotide polymorphisms (SNPs) affecting genes such as X-ray repair cross-complementing group 1 and 3 ($XRCC1$ and $XRCC3$), glutathione S transferase Pi 1 ($GSTP1$), and $RAD51$ recombinase.

We report a case of a breast cancer patient with SNPs in the aforementioned genes who developed an unpredictable severe or grade 3 (scored with SOMA-LENT system)6 subcutaneous fibrosis and skin telangiectasias with atrophy that evolved into a poor cosmetic outcome after adjuvant RT to the breast.

Case report

In 2012, a 60-year-old woman came to our attention with left breast cancer. In her clinical history, there were no autoimmune and vascular diseases, or diabetes. She had a moderately differentiated (grade 2) ductal carcinoma, with high expression of estrogen and progesterone receptors. She was treated with BCS on her external superior mammary quadrant and sentinel lymph node biopsy (stage pT1c pH0sn Er+ Pr+ Her 2+), followed by radiotherapy and adjuvant letrozole. In February 2012, she received adjuvant radiotherapy to the whole residual breast with three-dimensional (3D) conformal technique, 6 MV photons, and multileaf collimator customized beams with a standard fractionation of 2 Gy (50 Gy total), followed by a 10 Gy boost with a 12 MeV electron beam to the tumor bed.

During the treatment, she did not develop any acute skin reaction. Ten months later, the patient returned to our attention when complaining of hemorrhagic skin of the central-inferior quadrant of the irradiated breast, which was surrounded by multiple and frail telangiectasias. During the first 3 weeks, the lesion began to enlarge, and ultimately consisted of a big hemorrhagic morula, surrounded by several pustules, and outlined by an edematous circular edge (Figure 1). Two weeks later, the burst pustules released hemosiderinic products onto the skin. Two months later, the initially involved area became pale and avascular, and was covered by a transparent epithelial coat surrounded by multiple frail and thin telangiectasias (Figure 2). These phenomena recurred every 4 to 6 months, involving at least the entire irradiated breast. The breast was severely retracted and distorted with edema of the subcutaneous plane and induration in the central part near the nipple area, with peripheral telangiectasias (Figure 3). We decided to review the RT treatment plan for possible errors in the radiation planning and delivery, and to check for possible under-estimated high hot spot (highest skin dose) areas, which could explain this phenomenon. However, the execution of the RT treatment was correct; in the evaluation plan the configuration of the isodoses, the dose/fraction, and the effective total dose administered were accurate. In the revision of the plan, only 105% little hot spot areas in the upper external part of the breast were recorded, while the area of the boost was in the superior external quadrant, outside the involved fibrotic breast.
To exclude a local relapse and to avoid a pressed trauma to the affected breast by the mammography, a breast magnetic resonance imaging (MRI) was prescribed. Breast MRI showed no relapse and a contrast enhancement of the dermal-epidermal surface with thickening of the skin contour as shown in Figure 4A and B. To exclude the suspicion of an active autoimmune connective-tissue skin syndrome, the patient underwent patch biopsy of the involved area. The biopsy revealed findings of chronic inflammatory diseases, such as panniculitis and chronic radiodermatitis, characterized by fibrosis and dermo-epidermal strippings, telangiectasias with thin and frail vessels (Figure 5). At this point, we hypothesized the possible role of polymorphisms in genes involved in DNA repair mechanisms. We therefore tested for SNPs in genes of interest on a peripheral blood sample using polymerase chain reaction and pyrosequencing. The tested genes were GSTP1 (A313G), XRCC1 (G28152A), XRCC3 (A4541G and C18067T), RAD51 (G135C), CYP3A4*1B, and CYP19A1 (C268T and G410T). The result showed heterozygous mutations in XRCC1 G28152A (T/C) and XRCC3 C18067T (A/G), homozygous mutation in GSTP1 A313G (G/G), and wild-type XRCC3 A4541G (A/A) and RAD51 G135C (G/G).

The patient was informed that she was a carrier of these genetic alterations, and that they could be responsible for the late toxicity and worse cosmetic outcome after radiotherapy. She was observed with close follow-up and delivery of the necessary topical medications with the aim of curing the radiation-induced skin damage. Written informed consent was obtained from the patient for publication of the case details and images in this paper.

**Discussion**

BCS followed by adjuvant RT is replacing mastectomy as the standard treatment for early breast cancer. Large clinical trials with a median follow-up of 20–30 years have shown that BCS plus RT is safe and effective, achieving an excellent cosmetic outcome in approximately 80% of patients.7 Standard adjuvant RT consists of whole breast radiotherapy with 50 Gy in 25 daily fractions with or without a boost of 10 Gy. Nowadays, it is performed worldwide with conformal 3D forward or inverse–planned techniques. Nevertheless, the benefit of RT is also associated with adverse effects in terms of acute and late normal tissue toxicity as summarized in the “therapeutic ratio” concept.2 Radiation-induced adverse reactions are commonly classified as early or late effects, depending on the time of clinical symptom manifestation and the α/β ratio of the involved tissue. Acute-early effects occur within a few weeks after starting RT. They often involve rapidly proliferating tissues such as normal epithelial tissues, which are characterized by high α/β ratio. These effects are usually transient and related to an interruption of epithelial-cell generation, followed by thinning or denudation of epithelia and consequent healing. Chronic-late effects develop in months to some years after completion of RT, as in our patient. They involve tissues with a low α/β ratio and slow cell turnover.8,9 These events are usually more persistent and troublesome,
including chronic inflammatory processes, vascular changes, fibrosis, and atrophy. Radiobiology tells us that tissue radiosensitivity depends on the α/β ratio of the tissue and on the 5 Rs (repair, reassortment, repopulation, reoxygenation, and radiosensitivity) of the irradiated tissues, but it may also be influenced by environmental factors such as drugs. In breast cancer, adjuvant chemotherapy and hormone therapy have been acknowledged to influence radiosensitivity of the residual breast or the underlying irradiated normal tissues. Bentzen et al reported that the use of adjuvant CMF was responsible for the development of subcutaneous fibrosis after RT, showing a “shift on the left” of the plotted normal-tissue complication dose-response curve.11 Regarding the role of hormone therapy, the question remains controversial. The use of tamoxifen seems to cause lung fibrosis after adjuvant breast radiotherapy, while aromatase inhibitors seem to protect from lung fibrosis after adjuvant breast radiotherapy.4,5 However, our patient did not receive chemotherapy or tamoxifen treatment. Thus, in the absence of these “external factors”, as in our patient, a possible genetic explanation of an altered normal tissue radiosensitivity due to the presence of these SNPs should be hypothesized. Thus, we have analyzed all the available radiogenomic studies concerning the impact of SNPs in DNA repair genes in radiation-induced damage. Ionizing radiation has been demonstrated to produce its biological effects by generation of short-lived but highly reactive DNA radicals that evolve into stable and long-lived DNA lesions such as single-strand breaks and double-strand breaks (DSBs), leading to cell death.12,13 Damage repair is mediated by hundreds of genes involved in DNA repair machinery, such as DNA damage recognition, DNA repair pathways (including nonhomologous end joining of DSBs, homologous recombination repair of DSBs, and base excision repair of other types of single and simple clustered lesions), activation of cell-cycle checkpoints, signal transduction, and oxidative stress responses, as well as the apoptotic and premature senescence pathways.14 Allelic variations in the sequence of these genes, such as brief repeating sequences or SNPs, have been considered by radiogenomic studies to play a role in the development of post-radiation acute and late toxicities.15 The most studied SNPs are found in a few genes, including GSTP1 (A313G), XRCC1 (G28152A, rs25487), XRCC3 (A4541G), XRCC3 (C18067T), and RAD51 (G135C).

Our patient showed a mutation of XRCC1 (T/C G28152A rs25487) in the heterozygous state. XRCC1 encodes a protein involved in single base excision-repair (BER), which is the most common repair after damage induced by X-rays, reactive oxygen species, and alkylating agents. XRCC1 is a scaffold protein that coordinates both with the initial and late steps of abasic site restoration via multiple protein-protein interactions.16 By accurate analyses of radiogenomic studies from the literature, this SNP seems to play an important role in increasing the sensitivity to ionizing radiations.17,18 Moullan et al have hypothesized that distinct combinations of XRCC1 polymorphisms could be associated with the possibility of developing an adverse response to RT.19 A recent meta-analysis of several studies investigating the role of XRCC1 polymorphisms, in mostly Caucasian patients, on acute and late normal tissue reactions to irradiation revealed controversial findings.20 On the other hand, studies have found that SNPs that are associated in BER genes such as APE1 may have a protective effect against radiation-induced acute and late damage in Caucasian breast cancer patients.21,22 Thus, the predictive value of XRCC1 polymorphisms on late post-radiation breast toxicity remains unclear, in spite of many single investigational attempts made to validate this correlation. In fact, Andreassen et al, in their analysis, concluded that XRCC1 Arg399Arg genotype could be associated with post-radiation breast fibrosis, but in a follow-up cohort study they were unable to confirm these data.23,24

Most recently, a study investigating the predictive value of ten SNPs in four genes involved in DNA damage repair, including XRCC1 rs25487, on late toxicity after radiotherapy in breast cancer patients has been conducted using a state of the art design with replications. In the discovery cohorts, these SNPs were not associated with either skin toxicity or fibrosis (p<0.05), and in the replication cohorts, none of them were statistically significantly associated with any of the late toxicity endpoints investigated.25 However, in vitro and in vivo studies have found a strong link between haplotypes of XRCC1 and late radiation injury in irradiated breast. In a prospective study, XRCC1 SNPs (rs1799782 and rs25487) were significantly associated with adverse reactions to RT, such as altered pigmentation (p = 0.03) and telangiectasia (p = 0.01).26 Moreover, it is still unclear if late post-radiation sequelae could be under multiple-gene or single-gene control. Azriva et al, in an “in vitro” study, demonstrated that four or more SNPs in DNA repair genes controlled the development of severe late radiation-induced side effects, while Giottopoulos et al observed that fibrosis and telangiectasia could be under separate genetic control.27,28 The authors showed that the XRCC1 Arg399Gln SNP was associated specifically with late telangiectasia but not fibrosis, which was associated with transforming growth factor B1 509T (TGF-B1 509T).28

The genetic signature of our patient included a heterozygous XRCC3 (A/G) C18067T mutation associated with...
a wild-type *XRCC3* A4541G. *XRCC3* is also a member of the RAD51-related protein family that participates in homologous recombination repair of DSBs and plays an important role in maintaining chromosome stability. Note-  
worthily, DNA DSBs occur frequently after irradiation and are considered potent inducers of mutations and cell death.29,30  
The *XRCC3* C18067T mutation found in our patient is also known as *XRCC3* p.Thr241Met (rs861539) and is the most  
commonly reported polymorphism in *XRCC3*. The *XRCC3* protein has a low repair activity and a high in vitro radio-  
sensitivity that promotes chromosome instability and cell’s  
inability to repair radiation injury.31 Several meta-analyses  
have also demonstrated an association between the *XRCC3*  
p.Thr241Met polymorphism and the risk of breast cancer  
development, mainly in Asian population.32 The association  
between *XRCC3* polymorphisms and the risk of radiation-induced adverse effects has been evaluated in many studies  
using scoring systems or Q-Q plots to predict normal tissue  
response in radiosensitive patients, but the results have been  
controversial.26  
A robust support for our findings comes from a recent  
meta-analysis that found the *XRCC3* p.Thr241Met polymor- 
phism to be significantly associated with early adverse effects,  
such as acute skin toxicity and mucositis, mostly in patients  
irradiated for head and neck cancer.33 This SNP was signifi- 
cantly correlated with an increased risk of adverse effects in  
head and neck (*p* = 0.0003) and breast (*p* = 0.04) irradiation.  
In a subgroup analysis, the authors observed a significant  
association between this specific SNP and radiotherapy- 
induced fibrosis (*p* = 0.05). Moreover, the co-expression  
of the aforementioned SNP and the *XRCC3* rs861534 (*r^2* =  
0.96) seems to increase the risk of subcutaneous fibrosis.23  

Our patient also harbored homozygous *GSTP1* A313G  
(G/G) mutation. The glutathione S-transferases are a fam- 
ily of enzymes that play important roles in detoxification  
by catalyzing the conjugation of many hydrophobic and  
electrophilic compounds with reduced glutathione and thus  
play an important role in cell resistance to oxidative stress.34  
Falvo et al showed that moderate fibrosis (>grade 2) or fatty  
necrosis were more frequent in patients with than without  
*GSTM1* mutation (64% vs. 38%; *p* = 0.047), concluding  
that this mutation could be useful for predicting late toxic- 
ity in breast cancer patients treated with single shot partial  
breast irradiation.35 Terrazzino et al, in a retrospective study,  
evaluated the association between the risk of subcutane-  
ous fibrosis in irradiated breast cancer patients and eight  
polymeric variants in six candidate genes related to DNA  
repair mechanisms, oxidative stress response, and fibroblast  
proliferation and differentiation. The results suggested that  
polymorphisms in *GSTP1, GSTA1,* and *TGFB1* might con- 
tribute to the occurrence of grade 2–3 skin fibrosis (graded  
with SOMA-LENT system).36  
Although data regarding the association of these SNPs  
and post-radiation late normal tissue injury have been  
controversial, we could certainly conclude that the combi- 
nation of heterozygous mutations in *XRCC1* G28152A  
(T/C) and *XRCC3* C18067T (A/G) and homozygous mutation  
in *GSTM1* A313G (G/G) may have played important  
roles in the development of severe late tissue toxicity in  
our patient.  

**Conclusion**  
When a severe subcutaneous or cutaneous post-radiation  
fibrosis develops in the absence of pathological or technical  
explanations, tests for SNPs involving DNA repair genes,  
such as *GSTM1* (A313G), *XRCC1* (G28152A), *XRCC3*  
(A4541G and C18067T), and *RAD51* (G135C), should be  
considered. Knowledge of the molecular basis of radiosensi- 
tivity could be useful in identifying extremely radiosensitive  
individuals who may not tolerate RT as a treatment option or  
to exclude these predisposed patients from dose escalation  
or hypofractionation.  

**Disclosure**  
The authors report no conflicts of interest in this work.  

**References**  
1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S,  
surgery on 10-year recurrence and 15-year breast cancer death: meta-  
analysis of individual patient data for 10,801 women in 17 randomised  
2. Bentzen SM. Preventing or reducing late side effects of radiation ther- 
6(9):702–713.  
3. Skoczylas JZ, Bentzen SM, Overgaard M, Overgaard J. Time course of  
radiobiological lung density changes after postmastectomy radiotherapy.  
4. Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy- 
related lung fibrosis enhanced by tamoxifen. *J Natl Cancer Inst*.  
6. Denekamp J, Bartelink H, Rubin P. Correction for the use of SOMA  
versus mastectomy for stage I–II breast cancer: 20 year follow-up of  
412–419.  
8. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radia- 
tion on normal tissue: consequences and mechanisms. *Lancet Oncol*.  


